Rubius Therapeutics (Rubius Therapeutics) Price-to-Tangible-Book : 0.34 (As of May. 07, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Rubius Therapeutics Price-to-Tangible-Book?

As of today (2024-05-07), Rubius Therapeutics's share price is $0.057. Rubius Therapeutics's Tangible Book per Share of Dec. 2022 for the quarter that ended in Dec. 2022 was $0.17. Hence, Rubius Therapeutics's Price to Tangible Book Ratio of today is 0.34.

The historical rank and industry rank for Rubius Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

RUBY's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.73
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Rubius Therapeutics's share price is $0.057. Rubius Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2022 was $0.17. Hence, Rubius Therapeutics's P/B Ratio of today is 0.34.

Rubius Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Rubius Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rubius Therapeutics Price-to-Tangible-Book Chart

Rubius Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Tangible-Book

Get a 7-Day Free Trial

3.24

2.77

4.35

4.88

1.05

Rubius Therapeutics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Price-to-Tangible-Book	Get a 7-Day Free Trial															4.88	3.69	0.80	1.07	1.05

Competitive Comparison of Rubius Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Rubius Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rubius Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rubius Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Rubius Therapeutics's Price-to-Tangible-Book falls into.

Rubius Therapeutics Price-to-Tangible-Book Calculation

Rubius Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2022 )
	=	0.057	/	0.167
	=	0.34

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Rubius Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Rubius Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Rubius Therapeutics (Rubius Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rubius Therapeutics Inc (OTCPK:RUBY) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

124 Washington Street, Suite 101, Foxborough, MA, USA, 02035

Website

https://www.rubiustx.com

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Executives

Dannielle Appelhans	officer: CEO and President	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Pablo J Cagnoni	director, officer: Chief Executive Officer	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laurence A. Turka	officer: Chief Scientific Officer	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139
Susanne Schaffert	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
David R Epstein	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Maiken Keson-brookes	officer: CLO & Corp. Secretary	35 OAK HILL ROAD, FAYVILLE MA 01745
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Jose Carmona	officer: Chief Financial Officer	C/O INNOCOLL HOLDINGS PLC, 3803 WEST CHESTER PIKE, NEWTOWN SQUARE PA 19073
Christina M. Coughlin	officer: Chief Medical Officer	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139